commd7 Gene Expression in ALL

October 20, 2022 updated by: Marwa Saad Mohamed Mahrous, Assiut University

The Copper Metabolism MURR1 Domain 7 (COMMD7) Gene Expression in Acute Lymphoblastic Leukemia

  • study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia.
  • investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Acute lymphoblastic leukemia (ALL) is a neoplastic disorder of lymphoid progenitor cells characterized by diverse cytogenetic and molecular abnormalities with peaks of prevalence for 2-5-year-old patients and those older than 50. Treatment strategies using risk-adapted chemotherapy cure more than 80% of childhood cases, but around 20 to 30% relapse developing serious complications including death.( 1) In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes.(2) The copper metabolism MURR1 domain (COMMD) protein family involved in tumor development and progression in several types of human cancer, but little is known about the function of COMMD proteins in hematological malignancy. (3) COMMD7, a member of the COMMD, which is located on chromosome 20q11.21, has been reported associated with tumor progression in human solid cancers [4]. COMMD7 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) cells, associated with poor prognosis. [5]. Another study revealed that COMMD7-overexpressed hepatocellular carcinoma (HCC) cells promoted the proliferation of naïve HCC cells (6) A recent study was found that high expression of COMMD7 is a potential biomarker for adverse outcomes and poor prognosis in AML. (7)

. However, to date, the expression of COMMD7 in acute lymphoblastic leukemia and its prognostic value remain unclear.

Study Type

Observational

Enrollment (Anticipated)

102

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The required sample size will be 102 subject (51 newly diagnosed patients with ALL and 51 controls )

Description

Inclusion Criteria:

  • Patients newly diagnosed with acute lymphoblastic leukemia , male or female at any age.

Exclusion Criteria:

  • history of anti-neoplastic therapy, such as chemotherapy or radiotherapy.
  • Any other types of cancers.
  • Any clinically systemic acute or chronic inflammatory disease/s within one months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
PATEINTS
51 patients newly diagnosed with acute lymphoblastic leukemia
Diagnostic test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
controls
51 normal persons
Diagnostic test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
Time Frame: BASELINE
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) TO DETECT EXPRESSION pattern in ALL
BASELINE

Secondary Outcome Measures

Outcome Measure
Time Frame
Correlation between the expression level of COMMD7 GENE with other diagnostic parameters and prognosis in ALL
Time Frame: baseline
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2022

Primary Completion (Anticipated)

April 1, 2024

Study Completion (Anticipated)

November 1, 2024

Study Registration Dates

First Submitted

October 20, 2022

First Submitted That Met QC Criteria

October 20, 2022

First Posted (Actual)

October 24, 2022

Study Record Updates

Last Update Posted (Actual)

October 24, 2022

Last Update Submitted That Met QC Criteria

October 20, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • commd7 gene expression in ALL

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ALL

Clinical Trials on Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe